PT1585548T - Composições e métodos de administração de agentes farmacológicos - Google Patents
Composições e métodos de administração de agentes farmacológicosInfo
- Publication number
- PT1585548T PT1585548T PT03799876T PT03799876T PT1585548T PT 1585548 T PT1585548 T PT 1585548T PT 03799876 T PT03799876 T PT 03799876T PT 03799876 T PT03799876 T PT 03799876T PT 1585548 T PT1585548 T PT 1585548T
- Authority
- PT
- Portugal
- Prior art keywords
- delivery
- compositions
- methods
- pharmacological agents
- pharmacological
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
- Y10S977/705—Protein or peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
- Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43231702P | 2002-12-09 | 2002-12-09 | |
US22551903A | 2003-12-03 | 2003-12-03 | |
US22554903A | 2003-12-04 | 2003-12-04 | |
US22558503A | 2003-12-05 | 2003-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1585548T true PT1585548T (pt) | 2018-10-17 |
Family
ID=32512525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT03799876T PT1585548T (pt) | 2002-12-09 | 2003-12-09 | Composições e métodos de administração de agentes farmacológicos |
Country Status (6)
Country | Link |
---|---|
KR (8) | KR20150108943A (pt) |
BR (1) | BR0317134A (pt) |
MX (1) | MXPA05006169A (pt) |
NZ (1) | NZ541142A (pt) |
PT (1) | PT1585548T (pt) |
WO (1) | WO2004052401A2 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1506203T3 (da) | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf |
CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
EP1853240A2 (en) * | 2005-02-18 | 2007-11-14 | Abraxis BioScience, Inc. | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury |
MX339142B (es) | 2005-02-18 | 2016-05-13 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN100358513C (zh) * | 2005-04-07 | 2008-01-02 | 常州市第四制药厂有限公司 | 一种丙泊酚注射液的制备工艺 |
CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
EP3659589A1 (en) | 2005-08-31 | 2020-06-03 | Abraxis BioScience, LLC | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
WO2007069272A2 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
DE602007004124D1 (de) * | 2006-08-23 | 2010-02-11 | Blue Medical Devices B V | Medizinischer stent mit einer kombination aus melatonin und paclitaxel |
JP2010502603A (ja) * | 2006-08-31 | 2010-01-28 | アブラクシス バイオサイエンス, エルエルシー | 血管形成を阻害し、血管形成関連疾患を処置する方法 |
EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
SI2131821T1 (sl) * | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
EP2158316B1 (en) | 2007-05-11 | 2015-04-15 | Adynxx, Inc. | Gene expression and pain |
ES2435452T3 (es) | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
US20110009340A1 (en) * | 2008-02-19 | 2011-01-13 | Novartis Ag | Combination of an iron chelator and an immunosuppressant and use thereof |
KR101648734B1 (ko) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체 |
DK2419732T3 (da) | 2009-04-15 | 2019-12-16 | Abraxis Bioscience Llc | Prionfrie nanopartikelsammensætninger og fremgangsmåder |
KR101786142B1 (ko) | 2010-03-26 | 2017-10-17 | 아브락시스 바이오사이언스, 엘엘씨 | 간세포 암종의 치료 방법 |
BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
RU2589513C2 (ru) | 2010-03-29 | 2016-07-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
KR20180049180A (ko) | 2010-06-04 | 2018-05-10 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
EP2762558A4 (en) * | 2011-09-27 | 2015-05-20 | Public Univ Corp Yokohama City | METHOD FOR THE PRODUCTION OF WOVEN FABRICS AND ORGANS |
DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
CA2872901A1 (en) * | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
CN105246468A (zh) | 2013-03-14 | 2016-01-13 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
US20170000899A1 (en) * | 2013-11-26 | 2017-01-05 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
US10287583B2 (en) | 2014-08-15 | 2019-05-14 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
CN108024999A (zh) | 2015-06-29 | 2018-05-11 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
BR112020018910A2 (pt) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina |
KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56125317A (en) * | 1980-03-08 | 1981-10-01 | Nippon Mejifuijitsukusu Kk | Stable radioactive diagnosticum with radioactive metallic mark |
JPS59199636A (ja) * | 1983-04-26 | 1984-11-12 | Nippon Mejifuijitsukusu Kk | 放射性診断剤 |
EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
JPH06502177A (ja) * | 1990-10-16 | 1994-03-10 | バイオメディカル・フロンティアーズ・インコーポレイテッド | 磁気共鳴映像用ポリマー−デフェロキサミン−第2鉄付加物 |
DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
WO1997010850A1 (en) * | 1995-09-21 | 1997-03-27 | Andaris Limited | Transcytosis vehicles and enhancers for drug delivery |
DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
FR2775900A1 (fr) * | 1998-03-10 | 1999-09-17 | Charles Dumontet | Compositions medicamenteuses contenant de la deferoxamine pour la prevention des toxicites hematopoietique et tissulaire des anthracyclines et de leurs derives |
DE69932733T2 (de) * | 1998-10-16 | 2007-08-16 | The General Hospital Corp., Boston | Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene |
JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス, インク. | タンパク質の酸化分解を防ぐ方法及び組成物 |
-
2003
- 2003-12-09 WO PCT/US2003/038941 patent/WO2004052401A2/en active Application Filing
- 2003-12-09 KR KR1020157025001A patent/KR20150108943A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020057010482A patent/KR20050095826A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020147033814A patent/KR20140148502A/ko not_active Application Discontinuation
- 2003-12-09 PT PT03799876T patent/PT1585548T/pt unknown
- 2003-12-09 KR KR1020197008420A patent/KR20190034694A/ko not_active IP Right Cessation
- 2003-12-09 KR KR1020127011409A patent/KR20120068035A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020147003448A patent/KR20140027554A/ko not_active Application Discontinuation
- 2003-12-09 MX MXPA05006169A patent/MXPA05006169A/es unknown
- 2003-12-09 BR BR0317134-5A patent/BR0317134A/pt not_active Application Discontinuation
- 2003-12-09 KR KR1020187024645A patent/KR20180098702A/ko not_active Application Discontinuation
- 2003-12-09 NZ NZ541142A patent/NZ541142A/en not_active IP Right Cessation
- 2003-12-09 KR KR1020117011747A patent/KR20110079741A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050095826A (ko) | 2005-10-04 |
MXPA05006169A (es) | 2006-03-30 |
KR20150108943A (ko) | 2015-09-30 |
KR20140027554A (ko) | 2014-03-06 |
KR20110079741A (ko) | 2011-07-07 |
WO2004052401A3 (en) | 2005-02-17 |
KR20190034694A (ko) | 2019-04-02 |
KR20180098702A (ko) | 2018-09-04 |
KR20140148502A (ko) | 2014-12-31 |
WO2004052401A2 (en) | 2004-06-24 |
KR20120068035A (ko) | 2012-06-26 |
NZ541142A (en) | 2008-07-31 |
BR0317134A (pt) | 2005-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210032A1 (en) | Compositions and methods of delivery of pharmacological agents | |
PT1585548T (pt) | Composições e métodos de administração de agentes farmacológicos | |
AU2003259735A8 (en) | Small-mer compositions and methods of use | |
IL165910A0 (en) | Compositions of hyaluronic acid and methods of use | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
IL166608A0 (en) | Anti-microbial compositions and methods of using same | |
HK1153229A1 (en) | Minicell compositions and methods | |
AU2003219914A8 (en) | Intranasal administration of mc4-r agonists | |
GB0222091D0 (en) | Dental compositions and methods | |
AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
EP1663255A4 (en) | WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR | |
GB0303609D0 (en) | Novel therapeutic method and compositions | |
AU2003213120A8 (en) | Human rnase iii and compositions and uses thereof | |
EP1667656A4 (en) | COMPOSITIONS AND METHODS OF DISTRIBUTING BIOLOGICALLY ACTIVE AGENTS | |
EP1625141A4 (en) | GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF | |
EP1534293A4 (en) | INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION | |
ZA200505380B (en) | Compositions and methods of delivery of pharmacological agents | |
AU2003215264A8 (en) | Compositions and methods for delivery of skin cosmeceuticals | |
EP1461450A4 (en) | T-BET COMPOSITIONS AND METHOD OF USE THEREOF | |
AU2002366809A8 (en) | Syn3 compositions and methods | |
AU2003282593A8 (en) | Polyphenolamine composition and method of use | |
EP1553945A4 (en) | NITROXIDE RADIATION PROTECTION AND APPLICATION METHOD | |
EP1402892A4 (en) | ANTI-INFLAMMATORY AND ANTITUSSIVE COMPOSITIONS | |
GB0327050D0 (en) | Therapeutic methods compositions and uses | |
EP1696886A4 (en) | METHODS AND COMPOSITIONS FOR DELIVERY OF DRUGS |